These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37511423)

  • 1. Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model.
    Zizioli D; Ferretti S; Tiecco G; Mignani L; Monti E; Castelli F; Quiros-Roldan E; Zanella I
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
    Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
    Orkin C; Squires KE; Molina JM; Sax PE; Wong WW; Sussmann O; Kaplan R; Lupinacci L; Rodgers A; Xu X; Lin G; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C; Martin EA;
    Clin Infect Dis; 2019 Feb; 68(4):535-544. PubMed ID: 30184165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial.
    Orkin C; Squires KE; Molina JM; Sax PE; Sussmann O; Lin G; Kumar S; Hanna GJ; Hwang C; Martin E; Teppler H
    Clin Infect Dis; 2021 Jul; 73(1):33-42. PubMed ID: 33336698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis.
    Thompson M; Orkin C; Molina JM; Sax P; Cahn P; Squires K; Xu X; Rodgers A; Kumar S; Teppler H; Martin E; Hanna G; Hwang C
    Clin Infect Dis; 2020 Mar; 70(7):1336-1343. PubMed ID: 31121013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doravirine: a review.
    Colombier MA; Molina JM
    Curr Opin HIV AIDS; 2018 Jul; 13(4):308-314. PubMed ID: 29794817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.
    Feng M; Sachs NA; Xu M; Grobler J; Blair W; Hazuda DJ; Miller MD; Lai MT
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2241-7. PubMed ID: 26833152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental safety of nirmatrelvir in zebrafish (Danio rerio) embryos.
    Zizioli D; Ferretti S; Mignani L; Castelli F; Tiecco G; Zanella I; Quiros-Roldan E
    Birth Defects Res; 2023 Mar; 115(4):430-440. PubMed ID: 36373861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
    Nelson M; Winston A; Hill A; Mngqibisa R; Bassa A; Orkin C; Rassool M; Rodgers A; Teal V; Kumar S; Teppler H
    AIDS; 2021 Apr; 35(5):759-767. PubMed ID: 33587439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis.
    Orkin C; Molina JM; Lombaard J; DeJesus E; Rodgers A; Kumar S; Martin E; Hanna G; Hwang C
    Clin Infect Dis; 2020 Mar; 70(7):1344-1352. PubMed ID: 31121015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
    Scheibe K; Urbańska A; Jakubowski P; Hlebowicz M; Bociąga-Jasik M; Raczyńska A; Szymczak A; Szetela B; Łojewski W; Parczewski M
    Antivir Ther; 2021 May; 26(3-5):69-78. PubMed ID: 35485331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients.
    Gatell JM; Morales-Ramirez JO; Hagins DP; Thompson M; Keikawus A; Hoffmann C; Rugina S; Osiyemi O; Escoriu S; Dretler R; Harvey C; Xu X; Teppler H
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19532. PubMed ID: 25394041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabotegravir Exposure of Zebrafish (
    Zizioli D; Zanella I; Mignani L; Degli Antoni M; Castelli F; Quiros-Roldan E
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy.
    Bonafede M; Juday T; Lenhart G; Pan K; Hebden T; Correll T
    J Med Econ; 2013; 16(4):552-9. PubMed ID: 23391157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental toxicity of the triazole fungicide cyproconazole in embryo-larval stages of zebrafish (Danio rerio).
    Cao F; Souders CL; Li P; Pang S; Qiu L; Martyniuk CJ
    Environ Sci Pollut Res Int; 2019 Feb; 26(5):4913-4923. PubMed ID: 30569354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.